Gemfibrozil
- Generic Name
- Gemfibrozil
- Brand Names
- Lopid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22O3
- CAS Number
- 25812-30-0
- Unique Ingredient Identifier
- Q8X02027X3
- Background
Gemfibrozil is a fibric acid agent, similar to clofibrate, used to treat Type IIb, IV, and V hyperlipidemias. Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.
Gemfibrozil was granted FDA approval on 21 December 1981.
- Indication
Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions. Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.
- Associated Conditions
- Coronary Heart Disease (CHD), Fredrickson classification type IV Hyperlipidemia, Fredrickson classification type V Hyperlipidemia
A Study Investigating the Effect of Different Approved Medications on How the Body Processes the Study Compound RO7795081
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT06809608
- Locations
- 🇳🇱
ICON, Groningen, Netherlands
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
- Conditions
- Pain
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 30
- Registration Number
- NCT06064539
- Locations
- 🇺🇸
Prism Research-Site Number:8400001, Saint Paul, Minnesota, United States
Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
- Conditions
- CoughHealthy
- Interventions
- First Posted Date
- 2023-07-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Bellus Health Inc. - a GSK company
- Target Recruit Count
- 45
- Registration Number
- NCT05959447
- Locations
- 🇨🇦
GSK Investigational Site, Quebec City, Quebec, Canada
A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT05932303
- Locations
- 🇨🇦
Local Institution - 0001, Québec, CA, Canada
Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients.
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- Forest Hills Lab
- Target Recruit Count
- 32
- Registration Number
- NCT05931484
A Study to Investigate the Drug-drug Interactions (DDIs) of SKLB1028 With Itraconazole, Gemfibrozil or Rifampicin in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2021-10-06
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT05069870
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
A Study to Assess the Effect of Itraconazole, Phenytoin and Gemfibrozil on the Drug Levels of BMS-986166 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT04956627
- Locations
- 🇺🇸
Hassman Research Institute, Berlin, New Jersey, United States
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
- Conditions
- Juvenile Neuronal Ceroid Lipofuscinosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-11-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Polaryx Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04637282
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- Conditions
- Healthy Adult Subjects
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Reata, a wholly owned subsidiary of Biogen
- Target Recruit Count
- 61
- Registration Number
- NCT04008186
- Locations
- 🇺🇸
Covance Clinical Research Unit (CRU) Inc., Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.